Metastatic Castration Resistant Prostate cancer - Pipeline Insight, 2024

This Metastatic Castration Resistant Prostate cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Castration Resistant Prostate cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic Castration Resistant Prostate cancer Understanding

Metastatic Castration Resistant Prostate cancer: Overview

Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.

Metastatic Castration Resistant Prostate cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Castration Resistant Prostate cancer pipeline landscape is provided which includes the disease overview and Metastatic Castration Resistant Prostate cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Castration Resistant Prostate cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration Resistant Prostate cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Castration Resistant Prostate cancer. The therapies under development are focused on novel approaches to treat/improve Metastatic Castration Resistant Prostate cancer.

Metastatic Castration Resistant Prostate cancer Emerging Drugs

SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.

Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.

HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

Metastatic Castration Resistant Prostate cancer: Therapeutic Assessment

This segment of the report provides insights about the Metastatic Castration Resistant Prostate cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Metastatic Castration Resistant Prostate cancer

There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology

Phases

This report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Castration Resistant Prostate cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Castration Resistant Prostate cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Castration Resistant Prostate cancer drugs.

Metastatic Castration Resistant Prostate cancer Report Insights

• Metastatic Castration Resistant Prostate cancer Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic Castration Resistant Prostate cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic Castration Resistant Prostate cancer drugs?
• How many Metastatic Castration Resistant Prostate cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Castration Resistant Prostate cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Metastatic Castration Resistant Prostate cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic Castration Resistant Prostate cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Surface Oncology
• Regeneron Pharmaceuticals
• Clovis Oncology
• AstraZeneca
• Veru Healthcare
• Hinova Pharmaceuticals
• Zenith Epigenetic
• Eli Lilly and Company
• Lantern Pharma
• Astellas Pharma/Seagen
• Pfizer
• Progenics Pharmaceutical
• Molecular Insight Pharmaceuticals
• Bayer
• Accutar Biotechnology Inc
• Hinova Pharmaceuticals
• Taiho Oncology, Inc.
• Forma Therapeutics, Inc.
• Dizal Pharmaceuticals
• Amgen

Key Products

• SRF 617
• REGN 4336
• Rucaparib
• Capivasertib
• Sabizabulin
• Deutenzalutamide
• ZEN003694
• Abemaciclib
• Irofulven
• Enfortumab vedotin
• Talazoparib
• I-131-1095
• Pelgifatamab corixetan
• AC176
• HP518
• TAS3681
• FT-7051
• DZD2269
• TNB-585

This product will be delivered within 1-3 business days.